Background and Purpose—Stroke mortality has been declining since the early 20th century.
The reasons for this are not completely understood, although the decline is welcome. As a …

Background and Purpose—The efficacy and safety of different antiplatelet regimes for
prevention of stroke in patients at high risk were investigated in a systematic review and …

Sudden cardiac death (SCD) is known to occur in individuals with diverse diseases. Each
disease state has a specific etiology and pathophysiology, and is diagnosed and treated …

Background Studies show inconsistent results regarding the impact of CYP2C19 genotype
on the pharmacodynamics (PD) and clinical outcomes of ticagrelor. With the implementation …

Introduction In this article, authors report an inclusive discussion about the combinatorial
approach for the treatment of cardiovascular diseases (CVDs) and for counteracting the …

Background Drug–drug interactions are a major source of adverse drug events (ADEs).
Polypharmacy, age and the number of comorbid conditions are important predictors of …

Objectives Whether clopidogrel should be added to aspirin for stroke prevention remained
controversial for the risk of hemorrhagic complications. This meta-analysis was aimed to …

Background Patients with a history of a cardiovascular (CV) disease are at high risk of
suffering secondary major adverse cardiac events (MACE), namely death, nonfatal …

Background Platelet aggregation inhibitors (PAI) are among the most frequently prescribed
drugs in older people, though evidence about risks and benefits of their use in older adults is …

Background Non‐ST elevation acute coronary syndromes (NSTEACS) represent a spectrum
of disease including unstable angina and non‐ST segment myocardial infarction (NSTEMI) …